← Back to Search

Anticholinergic

experimental for Near-sightedness

Phase 3
Waitlist Available
Research Sponsored by The V.P. Vyhodcev Eye Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be younger than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline - 12 months
Awards & highlights

Summary

This trial tests if using a small amount of atropine eye drops can slow down worsening eyesight in Russian children with nearsightedness. The study aims to see if this treatment is safe and effective without causing significant side effects. Researchers are particularly interested in whether it works as well in Russian children as it does in Asian children. Atropine eye drops at low concentrations have been shown to slow myopia progression in children in various studies, including those conducted in East Asia and the USA.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline - 12 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline - 12 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
change in axial length
change in myopic progression rate
Secondary outcome measures
change in difference between manifest and cycloplegic refractions
change in positive relative accommodation
tear production

Trial Design

1Treatment groups
Experimental Treatment
Group I: experimentalExperimental Treatment1 Intervention
0.01% Atropine Sulfate solution in "Comfort Drops", nightly instillations to both eyes

Find a Location

Who is running the clinical trial?

The V.P. Vyhodcev Eye HospitalLead Sponsor
~13 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top